Yuhan Corporation

Diversified pharma

000100 · KOSPI · South Korea

Public Market Listing

000100KOSPI

KOSPI primary exchange listing

Live quotes, historical charts, and market capitalization for Yuhan Corporation are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
1Approved
1Phase 3 / Filed
5Phase 1–2 / Early
3Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Approved
EGFRSmall molecule
Non-Small Cell Lung Cancer
Sarpogrelate(Anplag)
Phase 3
Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule
Atherosclerotic Cardiovascular Disease
Phase 1/2
EGFR x 4-1BB (CD137)Multispecific antibody
Non-Small Cell Lung Cancer
Phase 1/2
HER2 exon 20 insertions; EGFR exon 20 insertionsSmall molecule
Non-Small Cell Lung Cancer
RosuampinNo recent activity
Preclinical / Unstaged
HMG-CoA reductase / Calcium channelSmall molecule
HypertensionAtherosclerotic Cardiovascular Disease
RosuvamibeNo recent activity
Preclinical / Unstaged
HMG-CoA reductase / NPC1L1Small molecule
Atherosclerotic Cardiovascular Disease
Preclinical / Unstaged
HMG-CoA reductase (rosuvastatin component) + NPC1L1 intestinal cholesterol transporter (ezetimibe component)Small molecule
Atherosclerotic Cardiovascular Disease

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
May 2027 (1)
LazertinibPhase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-05-31 · NCT06120140 · CT.gov ↗
What to watch
June 2027 (1)
YH32364Phase 1/2EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
Est. primary completion 2027-06 · NCT06975410 · CT.gov ↗
What to watch
August 2027 (1)
LazertinibPhase 2Carcinoma, Non-small-Cell Lung
Est. primary completion 2027-08-17 · NCT05498428 · CT.gov ↗
What to watch
2028 (2)
March 2028 (2)
LazertinibPhase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2028-03-02 · NCT07586202 · CT.gov ↗
What to watch
YH42946Phase 1/2NSCLC (Non-small Cell Lung Cancer), Solid Tumor
Est. primary completion 2028-03-15 · NCT06616766 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
LazertinibPhase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2029-05-23 · NCT06667076 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.5B—$241M—report ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.5B—$209M—report ↗
2023-FY$1.4B—$234M—report ↗